Metformin Enhances Doxorubicin Activity Against Cultured HepG2 Liver Cancer Cells
A laboratory study demonstrates that combining low-dose metformin with doxorubicin suppresses epithelial-to-mesenchymal transition and enhances antiproliferative effects in HepG2 liver ...










